MED12 and tumor of uterus: We thus assessed the β-catenin expression profile by immunohistochemistry in this uterine tumor series in order to see if the Wnt/β-catenin pathway was activated in these tumors, and if MED12 alterations were associated with a peculiar β-catenin pattern.